SRPT Sarepta Therapeutics, Inc.

Nasdaq Pharmaceutical Preparations DE CIK: 0000873303
AI RATING
SELL
75% Confidence

Investment Thesis

Sarepta demonstrates strong revenue growth (17.9% YoY) and operating margins (49%), but faces critical fundamental challenges with negative gross margins (-4%) and sharply negative operating cash flow (-$202.7M), indicating the company is not converting reported profits into actual cash generation. The combination of negative free cash flow, significant debt ($838.2M), and flat net income growth despite revenue expansion suggests structural profitability issues that are unsustainable.

Strengths

  • + Strong revenue growth of 17.9% YoY demonstrating market demand
  • + Excellent operating margin of 49% and net margin of 45.3%
  • + Strong liquidity with 4.63x current ratio and $464.4M cash position

Risks

  • ! Negative gross margin (-4%) indicates costs exceed revenue per unit sold - critical structural issue
  • ! Negative operating cash flow of -$202.7M contradicts reported profitability - suggests non-cash gains masking operational losses
  • ! Negative free cash flow (-$204.8M) with $838.2M debt burden is unsustainable without business model changes
  • ! Flat net income growth (0% YoY) despite 17.9% revenue growth indicates deteriorating profitability

Key Metrics to Watch

Financial Metrics

Revenue
730.8M
Net Income
331.0M
EPS (Diluted)
$2.88
Free Cash Flow
-204.8M
Total Assets
3.2B
Cash
464.5M

Profitability Ratios

Gross Margin -4.0%
Operating Margin 49.0%
Net Margin 45.3%
ROE 22.0%
ROA 10.4%
FCF Margin -28.0%

Balance Sheet & Liquidity

Current Ratio
4.63x
Quick Ratio
2.62x
Debt/Equity
0.56x
Debt/Assets
52.7%
Interest Coverage
N/A
Long-term Debt
838.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-07T10:38:00.618065 | Data as of: 2026-03-31 | Powered by Claude AI